RESUMEN
OBJECTIVE: The aim of this study was to evaluate the association of serum magnesium levels with proton pump inhibitors (PPIs) use and other factors. METHODS: This was a cross-sectional study of 151 patients admitted with acute diseases in the Internal Medicine Division of the Hospital de Clinicas de Porto Alegre, after the exclusion of conditions that are commonly associated with hypomagnesemia: diarrhea; vomiting; chronic alcohol use; severely uncompensated diabetes mellitus; and chronic use of laxatives, diuretics or other drugs causing magnesium deficiency. RESULTS: All patients had normal serum magnesium levels. Serum albumin and creatinine levels were positively associated with serum magnesium levels, after adjusting for confounders. There was no difference between mean serum magnesium levels of PPI users and non-users, nor between men and women; there was also no correlation among age, serum phosphorus, and potassium levels with serum magnesium levels. Limitations of this study include the absence of an instrument for measuring adherence to PPI use and the sample size. CONCLUSION: The association of PPI use and hypomagnesemia is uncommon. Congenital defects in the metabolism of magnesium may be responsible for hypomagnesemia in some patients using this drug class.
OBJETIVO: O objetivo desse estudo foi verificar a associação do nível sérico do magnésio com o uso de inibidores de bomba de prótons (IBP) e outros fatores. MÉTODOS: Realizou-se estudo transversal com 151 pacientes admitidos com doenças agudas no serviço de medicina interna do Hospital de Clínicas de Porto Alegre. Foram excluídos aqueles pacientes com condições usualmente relacionadas à hipomagnesemia: diarréia; vômitos; diabéticos agudamente descompensados; uso crônico de laxantes, álcool, diuréticos ou outros fármacos relacionados. RESULTADOS: Todos os pacientes apresentaram níveis normais de magnésio. Albumina e creatinina sérica se associaram positivamente com os níveis de magnésio sérico, após ajuste para fatores confundidores. Não houve diferença no nível sérico de magnésio em usuários ou não-usuários de IBP ou entre homens e mulheres. Não houve correlação com idade, nível sérico de fósforo e potássio. As principais limitações desse estudo foram a ausência de instrumento para medir a adesão aos IBPs e o tamanho da amostra. CONCLUSÃO: A associação do uso de IBP e hipomagnesemia é rara. Defeitos congênitos no metabolismo do magnésio devem ser responsáveis pelo surgimento de hipomagnesemia em usuários de dessa classe de fármacos.
Asunto(s)
Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Adulto Joven , Deficiencia de Magnesio/inducido químicamente , Deficiencia de Magnesio/epidemiología , Magnesio/sangre , Inhibidores de la Bomba de Protones/efectos adversos , Creatinina/sangre , Métodos Epidemiológicos , Deficiencia de Magnesio/sangre , Deficiencia de Magnesio/diagnóstico , Albúmina Sérica/análisisRESUMEN
OBJECTIVE: The aim of this study was to evaluate the association of serum magnesium levels with proton pump inhibitors (PPIs) use and other factors. METHODS: This was a cross-sectional study of 151 patients admitted with acute diseases in the Internal Medicine Division of the Hospital de Clinicas de Porto Alegre, after the exclusion of conditions that are commonly associated with hypomagnesemia: diarrhea; vomiting; chronic alcohol use; severely uncompensated diabetes mellitus; and chronic use of laxatives, diuretics or other drugs causing magnesium deficiency. RESULTS: All patients had normal serum magnesium levels. Serum albumin and creatinine levels were positively associated with serum magnesium levels, after adjusting for confounders. There was no difference between mean serum magnesium levels of PPI users and non-users, nor between men and women; there was also no correlation among age, serum phosphorus, and potassium levels with serum magnesium levels. Limitations of this study include the absence of an instrument for measuring adherence to PPI use and the sample size. CONCLUSION: The association of PPI use and hypomagnesemia is uncommon. Congenital defects in the metabolism of magnesium may be responsible for hypomagnesemia in some patients using this drug class.
Asunto(s)
Deficiencia de Magnesio/inducido químicamente , Deficiencia de Magnesio/epidemiología , Magnesio/sangre , Inhibidores de la Bomba de Protones/efectos adversos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Creatinina/sangre , Métodos Epidemiológicos , Femenino , Humanos , Deficiencia de Magnesio/sangre , Deficiencia de Magnesio/diagnóstico , Masculino , Persona de Mediana Edad , Albúmina Sérica/análisis , Adulto JovenRESUMEN
OBJECTIVE: The objective of this study was to evaluate the presence of vitamin B12 deficiency and the factors associated with serum vitamin B12 levels in a sample of metformin-treated Brazilian diabetic patients. METHOD: Cross-sectional study. RESULTS: 144 patients were included. Serum vitamin B12 levels were low (< 125 pmol/L) in 10 patients (6.9%) and possibly low (125 - 250 pmol/L) in 53 patients (36.8%). Serum vitamin B12 levels were negatively associated with age (B = -3.17; ß= -0.171; p = 0.037) and duration of metformin use (B= -33.36; ß= -0.161; p = 0.048), and positively associated with the estimated intake of vitamin B12 (B= 67.96; ß= 0.249; p = 0.002). CONCLUSION: The present findings suggest a high prevalence of vitamin B12 deficiency in metformin-treated diabetic patients. Older patients, patients in long term treatment with metformin and low vitamin B12 intake are probably more prone to this deficiency.
Asunto(s)
Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Metformina/uso terapéutico , Vitamina B 12/sangre , Brasil , Estudios Transversales , Diabetes Mellitus Tipo 2/sangre , Femenino , Homocisteína/sangre , Humanos , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
OBJECTIVE: The objective of this study was to evaluate the presence of vitamin B12 deficiency and the factors associated with serum vitamin B12 levels in a sample of metformin-treated Brazilian diabetic patients. METHOD: Cross-sectional study. RESULTS: 144 patients were included. Serum vitamin B12 levels were low (< 125 pmol/L) in 10 patients (6.9 percent) and possibly low (125 - 250 pmol/L) in 53 patients (36.8 percent). Serum vitamin B12 levels were negatively associated with age (B = -3.17; β= -0.171; p = 0.037) and duration of metformin use (B= -33.36; β= -0.161; p = 0.048), and positively associated with the estimated intake of vitamin B12 (B= 67.96; β= 0.249; p = 0.002). CONCLUSION: The present findings suggest a high prevalence of vitamin B12 deficiency in metformin-treated diabetic patients. Older patients, patients in long term treatment with metformin and low vitamin B12 intake are probably more prone to this deficiency.
OBJETIVO: O objetivo deste estudo foi avaliar a prevalência de deficiência de vitamina B12 em pacientes diabéticos brasileiros tratados com metformina e os fatores associados aos níveis séricos de vitamina B12. MÉTODO: Corte transversal. RESULTADOS: 144 pacientes foram incluídos. Os níveis séricos de vitamina B12 foram baixos (< 125 pmol/L) em 10 pacientes (6,9 por cento) e possivelmente baixos (125 - 250pmol/L) em 53 pacientes (36,8 por cento). Os níveis séricos de vitamina B12 foram associados negativamente à idade (B = -3,17; β = -0,171; p = 0,037) e à duração do uso de metformina (B = -33,36; β= -0,161; p = 0,048) e positivamente com a ingestão estimada de vitamina B12 (B = 67,96; β = 0,249; p = 0,002). CONCLUSÃO: Estes resultados sugerem alta prevalência de deficiência de vitamina B12 em pacientes diabéticos tratados com metformina. Pacientes mais velhos, em uso de metformina há muito tempo e com ingestão baixa de vitamina B12 estão provavelmente mais predispostos a essa deficiência.
Asunto(s)
Femenino , Humanos , Persona de Mediana Edad , /tratamiento farmacológico , Hipoglucemiantes/uso terapéutico , Metformina/uso terapéutico , /sangre , Brasil , Estudios Transversales , /sangre , Homocisteína/sangre , Factores de TiempoRESUMEN
Pseudomixoma peritoneal (PMP) é uma doença incomum, caracterizada pela presença de coleções líquidas gelatinosas em abdome e pelve, com implantes mucinosos na superfície peritoneal. A maioria dos casos é associada a neoplasias apendiculares. Os sintomas mais importantes são aumento de volume abdominal, emagrecimento, dor abdominal e sintomas mimetizando apendicite aguda. Esta condição clínica progride com disseminação peritoneal, obstrução intestinal e comprometimento nutricional. O caso relatado é de uma paciente feminina, 68 anos, com emagrecimento, aumento de volume abdominal e massa anexial, causando hidronefrose bilateral. Laparotomia exploradora evidenciou massa ocupando cavidades intraperitonial e retroperitonial, originária de tumor apendicular. Após análise histopatológica, o diagnóstico final foi de pseudomixoma peritoneal secundário a neoplasia de apêndice
Pseudomyxoma peritonei (PMP) is an uncommon disease, characterized by the presence of gelatinous collections in abdominal and pelvic cavities, with mucinous implants on peritoneal surface. The majority of PMP cases are associated with appendiceal carcinomas. The most important symptoms are increasing abdominal girth, weight loss, abdominal pain, and symptoms mimicking an acute appendicitis. This entity has a borderline behavior with progression to peritoneal seeding, intestinal obstruction, and nutritional compromise. The case reported is of a 68-year-old woman with weight loss, increasing abdominal girth, and an adnexal mass. Exploratory laparotomy demonstrated a mass occupying intraperitonial and retroperitonial spaces, originating in an appendiceal tumor. After histopathology examination, the final diagnosis was pseudomyxoma peritonei, due to appendiceal tumor